Publications

22 Feb 2011
News

Why Innovation Is So Hard in Health Care - and How to Do It Anyway

21 Mar 2016
News

Valeant Analysts Aren't Alone in Thinking 'Sell' Is a Dirty Word

October 2002
Case

A Father's Love: Novazyme Pharmaceuticals, Inc.

By: Richard M.J. Bohmer and Bradley Campbell

John Crowley, CEO of Novazyme Pharmaceuticals, a start-up biotechnology firm developing an orphan drug to treat a rare lysosomal storage disorder from which his children suffer, must choose between a partnership and a buyout to have sufficient funds and support to get... View Details

Keywords: Technological Innovation; Business Startups; Partners and Partnerships; Financing and Loans; Governing Rules, Regulations, and Reforms; Sales; Price; Product Development; Motivation and Incentives; Decision Choices and Conditions; Pharmaceutical Industry; Pharmaceutical Industry

April 2010
Case

Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug

By: John A. Quelch and Heather Beckham

Metabical is a new weight loss drug from Cambridge Sciences Pharmaceuticals intended for moderately overweight individuals. In anticipation of final FDA approval, the senior director of marketing, Barbara Printup, prepares for the product launch and must make several... View Details

Keywords: Return On Investment; Forecasting; Pricing Policies; Demand Planning; Marketing Strategy; Price; Consumer Behavior; Investment Return; Forecasting and Prediction; Product Launch; Planning; Brands and Branding; Pharmaceutical Industry

March 2004 (Revised July 2004)
Case

UCB: Managing Information for Globalization and Innovation (A) (Abridged)

By: F. Warren McFarlan and Brian DeLacey

A medium-size European manufacturer of pharmaceuticals and chemicals faces a number of information strategy issues. The case focuses on the issues of coordinating international IT activities and day-to-day operations as well as balancing the company's IT applications... View Details

Keywords: Innovation and Invention; Information Technology; Operations; System; Corporate Strategy; Investment Portfolio; Globalization; Pharmaceutical Industry; Pharmaceutical Industry; Brussels

06 Apr 2016
News

Pfizer and Allergan call off their $160 billion merger after U.S. move to block inversions

Research Summary

Entry deterrence via strategic litigation

This paper analyzes the use of litigation by incumbents to deter entry by new firms. Specifically, I look at a context where incumbent firms own patents that confer a limited monopoly period in the market. In the US pharmaceutical industry, regulation provides for... View Details

October 2016 (Revised February 2017)
Teaching Note

Alvogen

By: Daniel Isenberg, William R. Kerr and Alexis Brownell

Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details

Keywords: Biotechnology; Globalization; Entrepreneurship; Biotechnology Industry

January 1997 (Revised July 1998)
Case

Dendrite International (Condensed)

By: John A. Deighton

This version has been shortened to concentrate on the issue of managing a long selling process and long post-sale account relationship. The focus on the pharmaceutical industry in the United States, Europe, and Japan is preserved. Broader questions of expansion into... View Details

Keywords: Customer Focus and Relationships; Marketing Strategy; Product Development; Sales; Expansion; Pharmaceutical Industry; Pharmaceutical Industry; Japan; Europe; United States

September 1995
Case

Ares-Serono

By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop

Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details

Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; Europe

August 1990 (Revised January 1992)
Case

Eli Lilly and Co. (B): Europe

By: Michael Y. Yoshino

Examines the challenges facing the company in light of the changing economic, regulatory, and competitive environment in the European pharmaceutical industry. Examines the steps taken by the company adapting to this changing situation as part of a total globalization... View Details

Keywords: Change Management; Economics; Global Strategy; Business or Company Management; Growth and Development Strategy; Adaptation; Competition; Pharmaceutical Industry; Europe

January 1995 (Revised November 2021)
Case

Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal

By: David J. Collis and Elizabeth Wynne Johnson

Covers the history of portfolio planning at CIBA-GEIGY, a leading Swiss chemical and pharmaceutical company, beginning with the introduction of the process in the mid-1980s. The discussion extends to the application of portfolio planning techniques to a specific... View Details

Keywords: Investment Portfolio; Corporate Strategy; Factories, Labs, and Plants; Chemicals; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland

Video

Dr. Silvia Gold

Dr. Silvia Gold, President of the Mundo Sano Foundation and co-founder of Grupo Insud, explains how patent expiration is important for innovation, recounting that her company has always won against large Western pharmaceutical companies that have sought legal action... View Details

December 2000 (Revised January 2001)
Background Note

Promise of Functional Foods, The

By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock

This case presents a definition of functional foods or nutraceuticals (food or food ingredients that could provide a health benefit beyond the traditional nutrients they contain), a description of some of the major obstacles to their commercialization and... View Details

Keywords: Food; Private Sector; Public Sector; Health; Product Development; Production; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry

15 Feb 2011
News

Who will blink in Genzyme, Sanofi price talks?

February 2009 (Revised December 2009)
Case

Merck: Global Health and Access to Medicines

By: V. Kasturi Rangan and Katharine Lee

The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details

Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry

July 2004 (Revised May 2005)
Case

Pfizer's Virtual CIO (Abridged)

By: F. Warren McFarlan and Brian DeLacey

Discusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent... View Details

Keywords: Decision Making; Cost Management; Organizational Culture; Strategy; Information Technology; Pharmaceutical Industry